Home › All Companies › BCDA › Annual Report

BioCardia, Inc. (BCDA) — Annual Report

AI-Powered SEC Filing Analysis

← All BCDA filings
Latest Annual Report Filed: 2026-03-24

Key Insights

  • The company completed several financing rounds in 2024 and 2025, including ATM offerings, warrant issuances, and common stock sales, which provided additional capital to support its operations.
  • BioCardia reported increases in research and development expenses as well as selling, general, and administrative expenses in 2024 and 2025, indicating ongoing investment in its product development and commercialization efforts.
  • The company disclosed customer concentration risk, with a significant portion of its revenue coming from a small number of customers, which could expose it to potential volatility.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for BioCardia, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.